Diferenças específicas de gênero em pacientes com artrite psoriática que recebem ustekinumabe ou inibidor do fator de necrose tumoral: Dados do mundo real
Rheumatology (Oxford) doi:10.1093/rheumatology/kead089.
Real-world data from the PsABio study indicated that females with PsA had more severe disease than males before the initiation of treatment. While both genders experienced treatment related improvements, fewer females than males were able to achieve a favourable disease state within 12 months. Treatment discontinuation and switching were also higher in females than males, due to lower efficacy and adverse events.